-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Raises Price Target to $13

Benzinga·10/31/2026 00:27:07
語音播報
Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and raises the price target from $10 to $13.